Temporary adjunctive cilostazol vs clopidogrel loading for ST-segment elevation acute myocardial infarction

Area of Science:

• Cardiology
• Pharmacology
• Interventional Cardiology

Background:

• Clopidogrel loading is standard for rapid platelet inhibition post-percutaneous coronary intervention (PCI).
• Limited data exists on the comparative efficacy of adjunctive cilostazol versus clopidogrel loading.

Purpose of the Study:

• To compare the clinical outcomes of adjunctive cilostazol with clopidogrel loading in ST-elevation acute myocardial infarction (STEMI) patients undergoing primary PCI.
• To evaluate the safety and efficacy of cilostazol as an alternative to standard clopidogrel loading.

Main Methods:

• Retrospective analysis of 212 STEMI patients undergoing primary PCI with drug-eluting stents.
• Patients received aspirin and either clopidogrel loading (n=100) or adjunctive cilostazol (n=112) instead of loading.
• 30-day clinical outcomes, including major adverse cardiac events and bleeding, were examined.

Main Results:

• No significant difference in major adverse cardiac events (9.0% vs. 7.1%, p=0.62) between clopidogrel loading and cilostazol groups.
• Similar rates of definite stent thrombosis (2 vs. 1 patient) and bleeding events (9.0% vs. 5.4%, p=0.30) were observed.
• Mean cilostazol duration was 6.2 days.

Conclusions:

• Temporary adjunctive cilostazol treatment is non-inferior to clopidogrel loading for major adverse cardiac events in STEMI patients.
• Cilostazol presents a potential alternative strategy for platelet inhibition in this patient population.
• Further research may elucidate the full potential of cilostazol in acute myocardial infarction management.